- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Gout
The Rheumatology Network gout clinical focus page provides information on the latest gout news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for gout drugs.
Low Serum Urate Associated with Weight Loss, Sarcopenia
August 18, 2022
“These observations suggest that the often-observed epidemiologic correlation between low serum urate and adverse health outcomes may be confounded."
Prevalence of Gout Reportedly Higher in Black Patients
August 15, 2022
Despite gout being largely associated with White men, new data suggest gout and hyperuricemia impart a larger burden on other demographic groups, including Black men, Black women, and White women.
COVID-19 Vaccine Minimally Impacts Risk of Gout Flares
August 11, 2022
"COVID-19 vaccines are effective against severity of SARS-COV-2 infection, but there has been a concern regarding their effect on the risk of flares in patients with gout, which are associated with health-related quality of life, healthcare resource utilization, and work productivity."
John K Botson MD, RPh, CCD: FDA Approval of Pegloticase Injection Plus Methotrexate for Gout Treatment
July 13, 2022
John K. Botson MD, RPh, CCD, weighs in on the recent FDA approval of pegloticase injection plus methotrexate for the treatment of uncontrolled gout.
FDA Approves Pegloticase Injection Plus Methotrexate for Patients with Uncontrolled Gout
July 08, 2022
The decision was based on results from the MIRROR trial, which evaluated the concomitant use of pegloticase with methotrexate.
Low-Dose Benzbromarone Superior to Low-Dose Febuxostat in Gout Treatment
July 07, 2022
In the prospective, open-labeled trial, patients were randomly assigned to receive either low-dose benzbromarone or low-dose febuxostat for 12 weeks.
FDA Decisions to Watch in Rheumatology in Second Half of 2022
June 29, 2022
The approval and implementation of new drugs can vastly improve quality of life and reduce signs and symptoms of disease burden in patients with rheumatic and dermatologic diseases.
Rheumatology Network: Best of EULAR 2022
June 28, 2022
Take a few minutes to discover Rheumatology Network's most-viewed EULAR 2022 coverage.
Rheumatology Network's Top 5: June 25, 2022
June 25, 2022
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 25, 2022.
Plasma Levels of Glycoprotein Acetyls Linked to Incident Gout
June 22, 2022
Investigators identified novel biomarkers of incident gout and replicated novel metabolomic biomarkers of gout, including plasma levels of glycoprotein acetyls.